The mean tumour volume in the control shRNA treatment group was significantly larger than in the NG2 shRNA treated group, where additionally, not all animals developed MR detectable tumours (i.e. 3 out of 8, Fig. 2B left boxes, p = 0.015, two-tailed t-test). This evidence concerns the gene CSPG4 and neoplasm.